Douglas Adkins

Dr. Douglas Adkins is a prominent professor of oncology at Washington University School of Medicine and a co-principal investigator in groundbreaking cancer research. He recently gained attention for leading a clinical trial that demonstrated the efficacy of pembrolizumab, an immunotherapy drug that significantly extends remission periods for patients with head and neck cancers. His work has been instrumental in advancing treatment options for these patients, marking a significant breakthrough in oncology.